logo
  Join        Login             Stock Quote

ISTA Pharma (ISTA) To File NDA For Prolensa In 1H-2012

 May 10, 2012 12:48 PM
 


(By Balaseshan) ISTA Pharmaceuticals Inc. (NASDAQ:ISTA) said it plans to file a New Drug Application (NDA) for Prolensa in the first half of 2012 after the late-stage studies met the efficacy endpoints.

Prolensa is being developed for the treatment of ocular inflammation and pain following cataract surgery.

The company presented results from the second of two Phase 3 studies of Prolensa, its once-daily topical nonsteroidal anti-inflammatory product candidate. These data were presented in a poster session at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held from May 6-10, in Fort Lauderdale, FL.

[Related -Merger Arbitrage Mondays – April 9, 2012]

The findings showed Prolensa met both the study's primary and secondary efficacy endpoints, producing statistically greater clearing of subjects' ocular inflammation by Day 15 and a greater proportion of subjects that were pain free at one day post-cataract surgery than placebo.

Additional data demonstrated that there were no serious drug-related ocular or systemic adverse events, and that Prolensa's safety profile was consistent with ISTA's currently marketed once-daily topical nonsteroidal anti-inflammatory (NSAID) compound, Bromday (bromfenac ophthalmic solution) 0.09%.

Last month, ISTA presented similar results from the company's first Phase 3 study in a poster session at the 2012 American Society of Cataract and Refractive Surgery (ASCRS) Symposium and Congress in Chicago, IL.

[Related -U.S. Stocks Retreat After Monday's Rally; Hot Stocks: APOL, LEN, PVH, MMR, DG, ISTA, MAPP, MKC]

Data from both studies were collected under a common protocol and conducted and analyzed as two independent studies in the U.S. Based on the results of the two Phase 3 studies, ISTA plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for Prolensa in the first half of 2012.

From 2005 until 2011, ISTA marketed Xibrom (bromfenac ophthalmic solution) 0.09% in the U.S. for twice-daily use for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery. In October of 2010, ISTA received FDA approval for once-daily Bromday and discontinued shipments of Xibrom in February 2011.

Bromday is currently the only once-daily treatment option in the $370 million U.S. ophthalmic nonsteroidal anti-inflammatory market. ISTA acquired the U.S. ophthalmic rights to bromfenac in May 2002 under a license from Senju Pharmaceuticals Co. Ltd.

A U.S. patent was issued to ISTA's licensor, Senju, for Prolensa, which expires in September 2025. Prolensa is an investigational drug and not yet available for commercial use.

ISTA stock remains unchanged from Wednesday's close of $9.07. The stock has been trading between $2.88 and $11.36 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageInitial Jobless Claims Rose Unexpectedly

Claims unexpectedly rose in the latest report through last weekend to breach 300,000 for the first time read on...

article imageAll Quiet on the Record High Front

What can we glean from the media’s lack of attention to the market’s recent record read on...

article imageThe Chip Maker Short Sellers Should Be Watching

Investing in semiconductor stocks is always tricky. Industry cycles can lead to bumps in the road for the read on...

article imageChicago Fed: US Economic Growth Slowed In October

The pace of US growth slowed more than expected in October, according to this morning’s update of the read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.